Accelerated Suppression of Primary Epstein-Barr Virus Infection in HIV-Infected Infants Initiating Lopinavir/Ritonavir-Based Versus Nevirapine-Based Combination Antiretroviral Therapy
Date
2014Author
Slyker, Jennifer A.
Corey, Casper
Kenneth, Tapia
Barbra, Richardson
Lisa, Bunts
Meei-Li, Huang
Dalton, Wamalwa
Sarah, Benki-Nugent
Grace, John-Stewart
Language
enMetadata
Show full item recordAbstract
We compared primary Epstein-Barr virus (EBV) infection and suppression between Kenyan human immunodeficiency virus–infected infants starting nevirapine-based vs lopinavir/ritonavir-based antiretroviral regimens. Although the rate of EBV infection was similar between groups, infants receiving lopinavir/ritonavir suppressed EBV more rapidly. Our findings suggest that specific antiretrovirals may potentially impact the risk of future EBV-associated malignancies.
Citation
Slyker, Jennifer A., et al. "Accelerated Suppression of Primary Epstein-Barr Virus Infection in HIV-Infected Infants Initiating Lopinavir/Ritonavir-Based Versus Nevirapine-Based Combination Antiretroviral Therapy." Clinical Infectious Diseases 58.9 (2014): 1333-1337.Publisher
University of Nairobi,
Collections
- Faculty of Health Sciences (FHS) [10385]